longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Instru	ction 1(b).			In	vest	tment Co	omp	any Act of	1940								
(Print or Ty	pe Response	s)		T													
1. Name and Address of Reporting Person* Ferguson James J. III				2. Issuer Name and Ticker or Trading Symbol Matinas BioPharma Holdings, Inc. [MTNB]							5. R	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH SUITE 302				3. Date of Earliest Transaction (Month/Day/Year) 06/17/2020							X	X Officer (give title below) Other (specify below) Chief Medical Officer					
(Street) BEDMINSTER, NJ 07921				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_1	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(City) (State) (Zip)			Table I - Non-Derivative Securities Acqu							quired,	nired, Disposed of, or Beneficially Owned						
(Instr. 3) Date			2. Transaction Date (Month/Day/Year	r) any		Date, if Code (Instr		() · · · · · · · · · · · · · · · · · ·		d of (D)	Owned Followi Transaction(s)		ecurities Beneficially ng Reported		Form:	7. Nature of Indirect Beneficial	
				(Month	ı/Day	Day/Year)		de V A	mount (D)		Ì	(Instr. 3 and 4)			Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
Reminder:	Report on a s	separate line for eacl	n class of securities b	oeneficial	ly ow	ned direct	ily o	Persons in this f	s who respo orm are not ntly valid Ol	t requi	red to	respond u				1474 (9-02)	
			Table II						sed of, or Be		lly Own	ned					
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security		3. Transaction Date (Month/Day/Year)	any	Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		of U Sect	7. Title and Am of Underlying Securities (Instr. 3 and 4)		Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Owners Form of Derivati Security Direct (I or Indire	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	e	Amount or Number of Shares		(Instr. 4)	(Instr. 4		
Stock option (right to buy)	\$ 0.815	06/17/2020		A	2	250,000		(1)	06/16/203	5()	nmon tock	250,000	\$ 0	250,000	D		
Repor	ting O	wners															
			Relationships														
Reporting Owner Name / Address		Director 10% Owner Off			ficer	Other											
Fergusor	Iames I	ш															

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Ferguson James J. III C/O MATINAS BIOPHARMA HOLDINGS, INC. 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER, NJ 07921			Chief Medical Officer				

Signatures

/s/ Keith A. Kucinski, attorney-in fact for James J. Ferguson III	06/19/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. Vesting is performance based and tied to achievement of (1) positive topline ENHANCE-IT data (the "Milestone"). The option vests as to 1/3 upon achievement of the Milestone, with the remaining options to vest 1/3 on the first anniversary of such Milestone and 1/3 on the second anniversary of such Milestone.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.